Markets· August 16, 2026 at 06:00 p.m.
US Pharma Industry Shifts Towards Chinese Science
Key takeaways
- US trails China in clinical drug development and supply chain
- Big Pharma signs billion-dollar deals for Chinese-developed medicines
- A third of new drugs licensed by Big Pharma come from Chinese labs
The United States has seen a significant shift in clinical drug development and supply chain towards China, according to a June Cure Innovation Index survey. This change is evident as Big Pharma signs billion-dollar deals for Chinese-developed medicines. Dr. Nathan Goodyear, an integrative medicine physician at Williams Cancer Institute, noted that roughly a third of the new drugs licensed by Big Pharma in recent years came from Chinese labs.
